These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 19649913)

  • 1. High-throughput pharmacokinetics: cassette dosing.
    Bayliss MK; Frick LW
    Curr Opin Drug Discov Devel; 1999 Jan; 2(1):20-5. PubMed ID: 19649913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.
    Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic theory of cassette dosing in drug discovery screening.
    White RE; Manitpisitkul P
    Drug Metab Dispos; 2001 Jul; 29(7):957-66. PubMed ID: 11408361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput screening for lead optimization: a rational approach.
    Bajpai M; Adkison KK
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):63-71. PubMed ID: 19649839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetic properties utilizing combined physicochemical, in vitro and in vivo screens.
    Caldwell GW
    Curr Opin Drug Discov Devel; 2000 Jan; 3(1):30-41. PubMed ID: 19649835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of bioisosteric groups in lead optimization.
    Olesen PH
    Curr Opin Drug Discov Devel; 2001 Jul; 4(4):471-8. PubMed ID: 11727312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput screening of biocatalytic activity: applications in drug discovery.
    Kumar RA; Clark DS
    Curr Opin Chem Biol; 2006 Apr; 10(2):162-8. PubMed ID: 16520085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
    Beaumont K; Smith DA
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whatever happened to cassette-dosing pharmacokinetics?
    Manitpisitkul P; White RE
    Drug Discov Today; 2004 Aug; 9(15):652-8. PubMed ID: 15279848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery.
    Smith NF; Raynaud FI; Workman P
    Mol Cancer Ther; 2007 Feb; 6(2):428-40. PubMed ID: 17308044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug selection in early drug development: screening for acceptable pharmacokinetic properties using combined in vitro and computational approaches.
    Sinko PJ
    Curr Opin Drug Discov Devel; 1999 Jan; 2(1):42-8. PubMed ID: 19649916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput screening applied to drug synthesis process development.
    Cannarsa MJ; Uno T; Larsen C
    Curr Opin Drug Discov Devel; 2000 Nov; 3(6):743-9. PubMed ID: 19649902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions.
    Ward KW; Coon DJ; Magiera D; Bhadresa S; Struharik M; Lawrence MS
    Xenobiotica; 2009 Mar; 39(3):266-72. PubMed ID: 19280525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits.
    Wunberg T; Hendrix M; Hillisch A; Lobell M; Meier H; Schmeck C; Wild H; Hinzen B
    Drug Discov Today; 2006 Feb; 11(3-4):175-80. PubMed ID: 16533716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of animal clearance using naïve Bayesian classification and extended connectivity fingerprints.
    McIntyre TA; Han C; Davis CB
    Xenobiotica; 2009 Jul; 39(7):487-94. PubMed ID: 19480555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of "N-in-One" dosing to create an in vivo pharmacokinetics database for use in developing structure-pharmacokinetic relationships.
    Shaffer JE; Adkison KK; Halm K; Hedeen K; Berman J
    J Pharm Sci; 1999 Mar; 88(3):313-8. PubMed ID: 10052989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.
    Gabrielsson J; Dolgos H; Gillberg PG; Bredberg U; Benthem B; Duker G
    Drug Discov Today; 2009 Apr; 14(7-8):358-72. PubMed ID: 19162219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of combinatorial chemistry and structure-based drug design.
    Antel J
    Curr Opin Drug Discov Devel; 1999 May; 2(3):224-33. PubMed ID: 19649950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermodynamics of binding interactions in the rational drug design process.
    Holdgate GA
    Expert Opin Drug Discov; 2007 Aug; 2(8):1103-14. PubMed ID: 23484875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.